Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers benefits outweigh the risks in COVID-19 hypertensive patients

J Med Virol. 2021 Apr;93(4):1873-1874. doi: 10.1002/jmv.26672. Epub 2020 Nov 22.

Authors

Areej Mohamed Ateya¹, Nagwa A Sabri¹

Affiliation

¹ Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.

No abstract available

Publication types

Letter
Comment

MeSH terms

Angiotensin Receptor Antagonists / adverse effects
Angiotensin-Converting Enzyme Inhibitors / adverse effects
Angiotensins
COVID-19*
Humans
Hypertension* / drug therapy
Hypertension* / epidemiology
Renin-Angiotensin System
SARS-CoV-2

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensins